Compare Stocks: CORT, ANVS, TEVA, and ONC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.06 -0.5%	$1.46	$1.01 ▼ $5.50	$44.94M	1.23	855,226 shs	246,342 shs
CORT Corcept Therapeutics	$120.27 +2.1%	$115.45	$28.66 ▼ $126.38	$12.98B	0.4	1.49 million shs	123,821 shs
ONC BeOne Medicines	$352.78 +1.1%	$358.64	$253.95 ▼ $385.22	$38.70B	0.61	304,920 shs	48,072 shs
TEVA Teva Pharmaceutical Industries	$41.81 +1.3%	$37.91	$18.83 ▼ $42.02	$48.68B	0.89	6.79 million shs	2.36 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-8.66%	-10.21%	-6.22%	-41.55%	-35.47%
CORT Corcept Therapeutics	-2.80%	-1.48%	+4.44%	+31.52%	+64.69%
ONC BeOne Medicines	-0.38%	-3.78%	+0.74%	+12.15%	+6.74%
TEVA Teva Pharmaceutical Industries	+0.40%	+5.55%	+11.37%	+30.53%	+105.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.06 -0.5%	$1.46	$1.01 ▼ $5.50	$44.94M	1.23	855,226 shs	246,342 shs
CORT Corcept Therapeutics	$120.27 +2.1%	$115.45	$28.66 ▼ $126.38	$12.98B	0.4	1.49 million shs	123,821 shs
ONC BeOne Medicines	$352.78 +1.1%	$358.64	$253.95 ▼ $385.22	$38.70B	0.61	304,920 shs	48,072 shs
TEVA Teva Pharmaceutical Industries	$41.81 +1.3%	$37.91	$18.83 ▼ $42.02	$48.68B	0.89	6.79 million shs	2.36 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-8.66%	-10.21%	-6.22%	-41.55%	-35.47%
CORT Corcept Therapeutics	-2.80%	-1.48%	+4.44%	+31.52%	+64.69%
ONC BeOne Medicines	-0.38%	-3.78%	+0.74%	+12.15%	+6.74%
TEVA Teva Pharmaceutical Industries	+0.40%	+5.55%	+11.37%	+30.53%	+105.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.25	Hold	$12.00	1,037.44% Upside
CORT Corcept Therapeutics	2.75	Moderate Buy	$138.17	14.88% Upside
ONC BeOne Medicines	3.00	Buy	$404.93	14.78% Upside
TEVA Teva Pharmaceutical Industries	2.92	Moderate Buy	$45.50	8.84% Upside

Current Analyst Ratings Breakdown

Latest CORT, ANVS, TEVA, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$40.00 ➝ $50.00
10/8/2026	ONC BeOne Medicines	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/8/2026	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$450.00 ➝ $459.00
10/7/2026	ONC BeOne Medicines	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$418.00 ➝ $420.00
10/5/2026	ONC BeOne Medicines	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/2/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/1/2026	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$425.00 ➝ $445.00
10/1/2026	TEVA Teva Pharmaceutical Industries	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$55.00
9/28/2026	CORT Corcept Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
9/24/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
CORT Corcept Therapeutics	$761.41M	17.08	$0.90 per share	134.25	$6.16 per share	19.53
ONC BeOne Medicines	$5.34B	7.25	$3.94 per share	89.65	$39.77 per share	8.87
TEVA Teva Pharmaceutical Industries	$17.26B	2.82	$3.79 per share	11.04	$6.88 per share	6.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.42	285.98	34.56	N/A	6.52%	8.26%	6.45%	11/4/2026 (Estimated)
ONC BeOne Medicines	$286.93M	$5.68	62.06	25.77	N/A	10.70%	14.23%	7.82%	N/A
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	69.63	13.75	3.82	4.08%	32.64%	6.34%	11/3/2026 (Estimated)

Latest CORT, ANVS, TEVA, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ANVS Annovis Bio	-$0.30	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	CORT Corcept Therapeutics	$0.8130	N/A	N/A	N/A	$323.90 million	N/A
11/3/2026	Q3 2026	TEVA Teva Pharmaceutical Industries	$0.71	N/A	N/A	N/A	$4.23 billion	N/A
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	3.47	3.47
CORT Corcept Therapeutics	N/A	2.86	2.77
ONC BeOne Medicines	0.17	3.40	3.06
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
CORT Corcept Therapeutics	93.61%
ONC BeOne Medicines	48.55%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	15.92%
CORT Corcept Therapeutics	20.70%
ONC BeOne Medicines	6.19%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	7	42.68 million	35.89 million	Optionable
CORT Corcept Therapeutics	730	108.10 million	85.72 million	Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	N/A
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

CORT, ANVS, TEVA, and ONC Headlines

Recent News About These Companies

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Gets Price Target Bump from JPMorgan Chase & Co.

October 14 at 1:13 AM | americanbankingnews.com

TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament

October 12 at 10:24 PM | barchart.com

Teva to Host R&D Day on Wednesday, November 11 in New York City

October 12 at 10:24 PM | finance.yahoo.com

Teva to Host R&D Day on Wednesday, November 11 in New York City

October 12 at 6:11 PM | financialpost.comF

Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026

October 12 at 5:51 PM | quiverquant.comQ

Teva to Host R&D Day on Wednesday, November 11 in New York City

October 12 at 5:45 PM | globenewswire.com

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co.

October 12 at 2:47 PM | marketbeat.com

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

October 12 at 1:10 PM | zacks.com

Teva wins FDA approval for once-monthly olanzapine injection

October 12 at 12:21 PM | manufacturingchemist.comM

Oppenheimer raises target for Teva stock to USD 52.00

October 12 at 12:21 PM | ad-hoc-news.deA

Teva Pharmaceutical Industries Limited - Depositary receipt price target increased by 22.35% to R$0.35

October 12 at 12:21 PM | msn.com

Teva Pharmaceutical Industries (TEVA) Stock Analysis: Exploring a 9.71% Potential Upside for Investors

October 12 at 12:21 PM | directorstalkinterviews.com

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

October 12 at 12:21 PM | finance.yahoo.com

FDA approves Teva’s monthly injection of olanzapine for schizophrenia

October 12 at 12:21 PM | pharmaceutical-technology.comP

Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs

October 12 at 12:21 PM | finance.yahoo.com

Oppenheimer Adjusts Teva Pharmaceutical Industries PT to $52 From $50, Maintains Outperform Rating

October 9, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives - Slideshow

October 9, 2026 | seekingalpha.com

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

October 9, 2026 | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

October 9, 2026 | seekingalpha.com

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

October 9, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High - Time to Buy?

October 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, ANVS, TEVA, and ONC Company Descriptions

Annovis Bio NYSE:ANVS

$1.06 -0.01 (-0.47%)

As of 11:20 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Corcept Therapeutics NASDAQ:CORT

$120.27 +2.47 (+2.10%)

As of 11:20 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

BeOne Medicines NASDAQ:ONC

$352.78 +3.70 (+1.06%)

As of 11:20 AM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Teva Pharmaceutical Industries NYSE:TEVA

$41.81 +0.56 (+1.35%)

As of 11:20 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CORT, ANVS, TEVA, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CORT, ANVS, TEVA, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CORT, ANVS, TEVA, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, ANVS, TEVA, and ONC Company Descriptions

Annovis Bio NYSE:ANVS

Corcept Therapeutics NASDAQ:CORT

BeOne Medicines NASDAQ:ONC

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CORT, ANVS, TEVA, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CORT, ANVS, TEVA, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CORT, ANVS, TEVA, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, ANVS, TEVA, and ONC Company Descriptions

Annovis Bio NYSE:ANVS

Corcept Therapeutics NASDAQ:CORT

BeOne Medicines NASDAQ:ONC

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools